Last reviewed · How we verify

NCT05213715: CP

The Effect Of Somatosensory Perceptıon And Proprıoceptıon On Upper Extremıty Functıonal Skılls

Completed Last updated 1 April 2022
What this trial tests

trial testing assessment in Cerebral Palsy in 45 participants. Completed in 28 February 2022.

Timeline
10 January 2022
Primary endpoint
20 February 2022
28 February 2022

Quick facts

Lead sponsorKahramanmaras Sutcu Imam University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment45
Start date10 January 2022
Primary completion20 February 2022
Estimated completion28 February 2022
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Kahramanmaras Sutcu Imam University

Who can join

Adults 6 to 18, any sex, with Cerebral Palsy or Somatosensory Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cerebral Palsy (CP) is a non-progressive neurodevelopmental disorder characterized by posture and movement disorders as a result of damage to the immature brain for any reason before, during or after birth.In addition to tone, postural and neuromuscular control in children with Cerebral Palsy; Problems are also observed in communication skills, perceptual and cognitive systems and sensory systems.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of assessment

Trials testing the same drug.

Other recruiting trials for Cerebral Palsy

Currently open trials in the same condition.

Other Kahramanmaras Sutcu Imam University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05213715.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing